TBK1/IKBKE inhibitors (Gilead/Dana-Farber Cancer Institute)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameTBK1/IKBKE inhibitors (Gilead/Dana-Farber Cancer Institute)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase TBK1 inhibitorsInhibitor of nuclear factor kappa-B kinase subunit epsilon inhibitors
TargetsInhibitor of nuclear factor kappa-B kinase subunit epsilonSerine/threonine-protein kinase TBK1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDana-Farber Cancer InstituteGilead Sciences Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A